Skip to content

Quick ratio at other companies

Biogen logo
BiogenBIIB
+1.6×
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
2.9×-0.2×
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
6.8×+0.9×
PTC Therapeutics logo
PTC TherapeuticsPTCT
2.4×-1.5×
BridgeBio Pharma logo
BridgeBio PharmaBBIO
1.5×-3.1×
TG Therapeutics logo
TG TherapeuticsTGTX
5.7×+2.6×

Other financials

Income statement

See full
Revenue$268.1M+9.7%
Gross profit$243.3M+8.6%
Operating income-$4.6M-124%
Net income$3.6M-80.8%
EPS (diluted)$0.02-81.8%

Balance sheet

See full
Cash & equivalents$282.2M+29.6%
Total debt$50.8M-9.3%
Total equity$1.2B+63.1%
Total assets$1.6B+41.8%

Cash flow

See full
Operating cash flow$34.0M+67.2%
CapEx$5.2M
Free cash flow$28.8M+41.6%

Valuation

See full
Market cap$3.87B+37.0%

Profitability

See full
Gross margin91.5%-0.6pp
Operating margin7.4%-16.2pp
Net margin34.3%+11.3pp
FCF margin18.9%

Returns & leverage

See full
Return on equity37.3%+0.1pp
Debt / equity0.0×
Current ratio3.6×+0.7×

Where this comes from

Calculated from Acadia Pharmaceuticals’s reported figures.

Based on the most recent quarter.

The official record: Acadia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Acadia Pharmaceuticals's quick ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Acadia Pharmaceuticals's quick ratio?
Acadia Pharmaceuticals (ACAD) reported quick ratio of 3.6× in Q1 2026.
How has Acadia Pharmaceuticals's quick ratio changed year-over-year?
Acadia Pharmaceuticals's quick ratio increased by 26.1% year-over-year, from 2.8× to 3.6×.
What is the long-term trend for Acadia Pharmaceuticals's quick ratio?
Over 5 years (2020 to 2025), Acadia Pharmaceuticals's quick ratio has grown at a -10.6% compound annual growth rate (CAGR), from 6.7× to 3.8×.
What does quick ratio mean?
Current assets excluding inventory, divided by current liabilities at the quarter end (the 'acid-test'). A stricter liquidity measure that excludes the least-liquid current asset.